Sonrotoclax received its first-in-world regulatory approval for R/R MCL.
The first-in-world approval of Sonrotoclax is a landmark event for BeiGene and a significant development for cancer patients globally, particularly in APAC where B-cell malignancies are prevalent. This approval validates BeiGene's R&D capabilities and its commitment to bringing innovative therapies to market. It offers a new hope for patients with limited treatment options and strengthens BeiGene's position in the oncology landscape.
This approval is highly relevant to APAC as it provides a novel treatment option for patients with B-cell malignancies in the region. BeiGene's strong presence in APAC means this drug will likely be a key focus for market access and patient support programs, addressing a critical unmet medical need in countries like China and others across Asia.
BeiGene社の新規BCL2阻害剤ソノロトクラックスが、再発・難治性（R/R）マントル細胞リンパ腫（MCL）の治療薬として世界で初めて承認を取得しました。この規制当局による承認は、B細胞悪性腫瘍の治療における重要な進展を意味し、治療選択肢が限られている患者に新たな治療法を提供します。本承認は、有効性と安全性を実証する堅牢な臨床試験データに基づいています。
Sign in to save notes on signals.
ログイン